Historical Valuation
Vanda Pharmaceuticals Inc (VNDA) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.90 is considered Undervalued compared with the five-year average of -19.53. The fair price of Vanda Pharmaceuticals Inc (VNDA) is between 7.55 to 12.77 according to relative valuation methord. Compared to the current price of 7.45 USD , Vanda Pharmaceuticals Inc is Undervalued By 1.38%.
Relative Value
Fair Zone
7.55-12.77
Current Price：7.45
1.38%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Vanda Pharmaceuticals Inc (VNDA) has a current Price-to-Book (P/B) ratio of 1.05. Compared to its 3-year average P/B ratio of 0.57 , the current P/B ratio is approximately 84.93% higher. Relative to its 5-year average P/B ratio of 0.99, the current P/B ratio is about 5.89% higher. Vanda Pharmaceuticals Inc (VNDA) has a Forward Free Cash Flow (FCF) yield of approximately -17.01%. Compared to its 3-year average FCF yield of -16.59%, the current FCF yield is approximately 2.53% lower. Relative to its 5-year average FCF yield of -6.90% , the current FCF yield is about 146.47% lower.
P/B
Median3y
0.57
Median5y
0.99
FCF Yield
Median3y
-16.59
Median5y
-6.90
Competitors Valuation Multiple
AI Analysis for VNDA
The average P/S ratio for VNDA competitors is 4.46, providing a benchmark for relative valuation. Vanda Pharmaceuticals Inc Corp (VNDA.O) exhibits a P/S ratio of 1.90, which is -57.38% above the industry average. Given its robust revenue growth of 18.06%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for VNDA
1Y
3Y
5Y
Market capitalization of VNDA increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of VNDA in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is VNDA currently overvalued or undervalued?
Vanda Pharmaceuticals Inc (VNDA) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.90 is considered Undervalued compared with the five-year average of -19.53. The fair price of Vanda Pharmaceuticals Inc (VNDA) is between 7.55 to 12.77 according to relative valuation methord. Compared to the current price of 7.45 USD , Vanda Pharmaceuticals Inc is Undervalued By 1.38% .
What is Vanda Pharmaceuticals Inc (VNDA) fair value?
VNDA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Vanda Pharmaceuticals Inc (VNDA) is between 7.55 to 12.77 according to relative valuation methord.
How does VNDA's valuation metrics compare to the industry average?
The average P/S ratio for VNDA's competitors is 4.46, providing a benchmark for relative valuation. Vanda Pharmaceuticals Inc Corp (VNDA) exhibits a P/S ratio of 1.90, which is -57.38% above the industry average. Given its robust revenue growth of 18.06%, this premium appears unsustainable.
What is the current P/B ratio for Vanda Pharmaceuticals Inc (VNDA) as of Jan 09 2026?
As of Jan 09 2026, Vanda Pharmaceuticals Inc (VNDA) has a P/B ratio of 1.05. This indicates that the market values VNDA at 1.05 times its book value.
What is the current FCF Yield for Vanda Pharmaceuticals Inc (VNDA) as of Jan 09 2026?
As of Jan 09 2026, Vanda Pharmaceuticals Inc (VNDA) has a FCF Yield of -17.01%. This means that for every dollar of Vanda Pharmaceuticals Inc’s market capitalization, the company generates -17.01 cents in free cash flow.
What is the current Forward P/E ratio for Vanda Pharmaceuticals Inc (VNDA) as of Jan 09 2026?
As of Jan 09 2026, Vanda Pharmaceuticals Inc (VNDA) has a Forward P/E ratio of -3.33. This means the market is willing to pay $-3.33 for every dollar of Vanda Pharmaceuticals Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Vanda Pharmaceuticals Inc (VNDA) as of Jan 09 2026?
As of Jan 09 2026, Vanda Pharmaceuticals Inc (VNDA) has a Forward P/S ratio of 1.90. This means the market is valuing VNDA at $1.90 for every dollar of expected revenue over the next 12 months.